ABVC BioPharma Receives Additional $100,000 Payment from OncoX, Advancing Oncology Licensing Strategy

ABVC BioPharma has received a $100,000 licensing payment from oncology partner OncoX BioPharma, marking the fifth such payment in 2025 and bringing total payments to $695,950 under their existing agreement. This transaction represents significant progress in ABVC's strategic shift toward becoming an asset-light international licensing platform with predictable revenue streams. The continued financial contributions from OncoX validate ABVC's multi-partner licensing approach and demonstrate tangible execution of its oncology revenue framework.

The importance of this development lies in the growing validation of plant-derived cancer therapies and the financial stability it provides ABVC during clinical development phases. OncoX specializes in developing oncology therapeutics derived from natural sources, with its lead candidate derived from Grifola frondosa (maitake mushroom) extract showing potential in treating triple-negative breast cancer, non-small-cell lung cancer, pancreatic cancer, and myelodysplastic syndrome. These treatments address some of the most challenging cancer types where conventional therapies often show limited effectiveness.

Beyond the immediate financial impact, ABVC's three-tier value-amplification model creates both short-term and long-term value for investors and the healthcare ecosystem. The short-term component includes licensing payments totaling $695,950 received to date, providing cash-flow visibility and demonstrating consistent milestone execution. The long-term value comes from a 5% royalty on net sales up to cumulative $55 million, creating sustainable, high-profit-margin recurring income. This model represents a strategic evolution from traditional research-focused biopharmaceutical companies toward more financially predictable business structures.

The broader financial outlook for ABVC appears promising, with consolidated data across all licensing partners showing a total contractual cash revenue pool potentially reaching $14.25 million, of which $2.14 million had been received as of October 2025. This financial stability is crucial for advancing clinical development while minimizing shareholder dilution through reduced dependence on equity financing.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that the continued licensing payments reflect progress in their partnership strategy and demonstrate the effectiveness of ABVC's licensing-driven business model in transforming research and development assets into recurring value creation. The collaboration between ABVC and OncoX extends beyond simple licensing, incorporating strategic partnerships with Japanese biomedical companies and academic institutions to co-develop precision gene-oriented therapies and anti-fibrosis technologies.

OncoX's expansion into cancer-supportive care and preventative health through proprietary natural ingredients, including the Lycogen extraction platform, positions the partnership to address adjacent markets including preventative medicine, chronic disease care, aesthetic medicine, and animal health. According to Allied Market Research, these cross-sector applications are projected to reach a global market size of $187 million by 2030. More detailed market information is available at https://www.prnewswire.com/news-releases/lycopene-market-to-reach-187-3-million-globally-by-2030-at-5-2-cagr-allied-market-research-301371075.html.

The strategic manufacturing collaboration with BioKey Inc., a U.S. FDA-registered facility, provides additional validation of the partnership's operational capabilities. With development and commercialization plans spanning the United States, Japan, Taiwan, and other key Asia-Pacific markets, the ABVC-OncoX collaboration represents a growing biotechnology network connecting U.S. and Asian markets. This global approach enhances the potential market reach for their developing therapies while diversifying regulatory and commercial risks across multiple jurisdictions.

For investors and the broader healthcare industry, this ongoing partnership demonstrates how biotechnology companies can create sustainable revenue models while advancing innovative treatments. The consistent licensing payments provide financial transparency and reduce the volatility often associated with clinical-stage biopharmaceutical companies. As plant-based therapies gain increased scientific validation and market acceptance, partnerships like the one between ABVC and OncoX may serve as templates for future biotechnology business models that balance innovation with financial sustainability.